Schrödinger 2026年第一季度每股收益为-0.81美元，未达预期26.56%；营收为5860万美元，超出预期21.78%，高于预期的4812万美元。 药物发现业务营收同比飙升124%；软件毛利率因托管许可模式转型，从80%降至69%。 运营支出同比下降4%至7800万美元；盘后交易中股价下跌0.31%至12.8美元，接近52周低点。 公司维持2026年业绩指引：ACV（年度合同价值）增 ...

Investors in Schrodinger Inc (Symbol: SDGR) saw new options begin trading today, for the June 2024 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Schrödinger’s fair value estimate has been trimmed slightly from US$21.38 to US$20.88, bringing it in line with the updated implied price target in the model. This mirrors recent Street research, ...

Schrodinger is a biotech company that uses machine learning, physics, and chemistry to speed up the drug discovery process, focusing on finding ligands that bind with proteins to treat diseases. The ...

Schrödinger, Inc. (NASDAQ:SDGR) is a scientific software and biotechnology company that specializes in developing computational tools and software for drug discovery and materials science. While the ...

Hi-tech drug discovery firm Schrödinger, Inc. (SDGR) is up 100% since its IPO earlier this year, and one of Wall Street‘s “most intriguing and mysterious” billionaires just cashed in. David Shaw, the ...

Detailed price information for Schrodinger Inc (SDGR-Q) from The Globe and Mail including charting and trades.

Schrodinger, Inc. SDGR shares ended the last trading session 14.1% higher at $24.34. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.